Status Epilepticus Clinical Trial
Official title:
Buccal, Intranasal or Intravenous Lorazepam for the Treatment of Acute Convulsions in Children in Blantyre, Malawi: a Randomized Trial
This study aims to address the hypothesis that Lorazepam (an anticonvulsant) is as effective when given via the intranasal or buccal route as the intravenous route in terminating convulsions in children.
Convulsions are common in children. Prompt treatment with an effective anticonvulsant
reduces longterm morbidity and mortality. The use of intravenous lorazepam as first line
therapy in acute childhood convulsions where venous access has been obtained is widely
accepted in developed countries. However, intravenous access can be a problem out of
hospital or in small children.
Benzodiazepines such as Lorazepam have long been the mainstay of first line therapy for
acute convulsions but there is insufficient clinical evidence as to the optimal mode of
administration when venous access has failed. Lorazepam can be given via the intranasal and
buccal route offering the potential to be as effective as intravenous lorazepam whilst being
easier to administer and avoiding the need for intravenous cannulation.
To date there are no large published studies that have evaluated the efficacy and safety of
intranasal or buccal lorazepam compared to intravenous lorazepam in the treatment of acute
convulsions. In this study we wish to address the urgent need to obtain randomized
controlled data in treating acute convulsions in children using a drug and delivery system
that is safe, effective and easy to use in our setting.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03883516 -
Improving Emergency Management of Status Epilepticus
|
N/A | |
Recruiting |
NCT03378687 -
A Clinical Study of Children With Status Epilepticus in China
|
N/A | |
Recruiting |
NCT00362141 -
Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus
|
Phase 2 | |
Recruiting |
NCT05140265 -
De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information
|
||
Active, not recruiting |
NCT04391569 -
Randomized Therapy In Status Epilepticus
|
Phase 3 | |
Recruiting |
NCT06017973 -
The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus
|
N/A | |
Completed |
NCT06334796 -
Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
|
Early Phase 1 | |
Recruiting |
NCT05491590 -
Patient-reported Outcome After Status Epilepticus
|
||
Recruiting |
NCT04421846 -
Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
|
N/A | |
Completed |
NCT02958605 -
Smartphone Apps for Pediatric Resuscitation
|
N/A | |
Completed |
NCT02239380 -
Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan
|
Phase 3 | |
Completed |
NCT01796574 -
Ketogenic Diet for Refractory Status Epilepticus
|
N/A | |
Completed |
NCT02381977 -
Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment
|
N/A | |
Completed |
NCT00004297 -
Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus
|
Phase 3 | |
Completed |
NCT03905798 -
LORA-PITA IV General Investigation
|
||
Recruiting |
NCT05591508 -
Ketogenic Diet for Status Epilepticus in Children Post Cessation of Convulsive Status Epilepticus
|
N/A | |
Completed |
NCT00735527 -
Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children
|
Phase 3 | |
Terminated |
NCT00265616 -
Treatment of Refractory Status Epilepticus
|
Phase 3 | |
Recruiting |
NCT06401707 -
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
|
Phase 2 | |
Enrolling by invitation |
NCT06403150 -
The Efficacy and Safety of Levetiracetam Versus Fosphenytoin in Convulsive Status Epilepticus
|
Phase 4 |